Annie wrote a contending response comment on the “Zionist safe space” contention in the teaching of Hebrew in Chicago-area schools, equating it to the teaching of communism.

Settler-colonialism (or colonialism in general) can no more be justified than a child abuser, a rapist, or a home invader excused for having had a tough childhood. I don’t see that working in the criminal justice system. My mind is simple enough to ask why we do not apply in the international arena the same laws we apply in the criminal justice system, and I am not saying it’s perfect. Obviously not. But thanks to how things are working now at least here in Scotland, I am able to leave my house in the morning, go where I need to go, do what I need to do, drive back and expect to be alive and unharmed as a female who is a migrant to this country, looks a wee bit darker than the average person here and speaks with a different accent. The same is not true for a Palestinian in Palestine, or for a Syrian, or for a lot of people caught up in a colonialist system, or its aftermath or in any supremacist system anywhere.

|| Mooser: … Damn, I think “Grover” has stumbled on a formula which makes Zionism impregnable. Simply call every criticism of Zionism an insult to the Jews. That should work. ||

© 2014 American College of Chest Physicians. This overview will demonstrate that cough is a common and potentially expensive healthcare problem. Improvement in the quality of care… [more]

jon 66: “How can one argue that ACTUAL hijacking, murder, suicide bombing, indiscriminate rocket attacks, stabbings, etc., are justified because one had ancestors in the area?”

“Zionism was not a form of colonialism because the Jews immigrating to Israel/Palestine were settling in the Jewish historic homeland.”

To separate the effects of elevated Ab titers from adjuvanting effects of unique Fc domains in the neutralizers, we selected polyclonal pools of Abs across the neutralizers and non-neutralizers that had equivalent titers and avidity. Specifically, gp120-specific binding titers and avidity were assessed across the top 10 neutralizers and the bottom 10 neutralizers (fig. S1A). Although gp120-specific titers were higher among the neutralizers, four individuals were selected from each group that had equivalent gp120-specific titers and avidity (encircled in red). Binding curves were performed to define the optimal concentration (1:30) of plasma to achieve equivalent bead occupancy (fig. S1, B and C).

We wondered whether the increased susceptibility to systemic candidiasis observed upon LMP7 inhibition would be treatable with antifungal agents like Amphotericin B (AmpB). Mice receiving vehicle or ONX 0914 were daily treated with 10 mg/kg AmpB. Strikingly, these mice, no matter if treated with vehicle or ONX 0914, were almost fully protected from weight loss (Supplementary Fig. S3A). Analyzing renal fungal burden revealed that independent of LMP7 inhibition, AmpB treatment resulted in almost complete clearance of the fungus on day 7 postinfection (Supplementary Fig. S3B).

BACKGROUND: Asthma and gastro-oesophageal reflux are both common medical conditions and often co-exist. Studies have shown conflicting results concerning the effects of lower oesophageal acidification as a trigger of asthma. Furthermore, asthma might precipitate gastro-oesophageal reflux. Thus a temporal association between the two does not establish that gastro-oesophageal reflux triggers asthma. Randomised trials of a number of treatments for gastro-oesophageal reflux in asthma have been conducted, with conflicting results. OBJECTIVES: The objective of this review was to evaluate the effectiveness of treatments for gastro-oesophageal reflux in terms of their benefit on asthma. SEARCH STRATEGY: The Cochrane Airways Group trials register, review articles and reference lists of articles were searched. SELECTION CRITERIA: Randomised controlled trials of treatment for oesophageal reflux in adults and children with a diagnosis of both asthma and gastro-oesophageal reflux. DATA COLLECTION AND ANALYSIS: Trial quality and data extraction were carried out by two independent reviewers. Authors were contacted for confirmation or more data. MAIN RESULTS: Nine trials met the inclusion criteria. Interventions included proton pump inhibitors (n=3), histamine antagonists (n=5), surgery (n=1) and conservative management (n=1). Treatment duration ranged from 1 week to 6 months. A temporal association between asthma and gastro-oesophageal reflux was investigated in 4 trials and found to be present in a proportion of participants in these trials. Anti-reflux treatment did not consistently improve lung function, asthma symptoms, nocturnal asthma or the use of asthma medications. REVIEWER’S CONCLUSIONS: In asthmatic subjects with gastro-oesophageal reflux, (but who were not recruited specifically on the basis of reflux-associated respiratory symptoms), there was no overall improvement in asthma following treatment for gastro-oesophageal reflux. Subgroups of patients may gain benefit, but it appears difficult to predict responders.

Huyết tương người âm tính Syphilis TP (46,2650%), Huyết tương người dương tính Syphilis TP (4,9718%)

Well, Zionist Rabbis recommend rape by Jewish soldiers, but not every Jewish person can live up to strict observance of the commands.

© 2018 GlaxoSmithKline Background: Mepolizumab has demonstrated favorable safety and efficacy profiles in placebo-controlled trials of 12 months¿ duration or less; however, long-term data are lacking. Objective: We sought to evaluate the long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma (SEA). Methods: COLUMBA (Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects, NCT01691859) was an open-label extension study in patients with SEA previously enrolled in DREAM (Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma, NCT01000506). Patients received 100 mg of subcutaneous mepolizumab every 4 weeks plus standard of care until a protocol-defined stopping criterion was met. Safety end points included frequency of adverse events (AEs), serious AEs, and AEs of special interest. Efficacy end points included annualized exacerbation rates, changes from baseline in Asthma Control Questionnaire 5 scores, and blood eosinophil counts. Immunogenicity was also assessed. Results: Overall, 347 patients were enrolled for an average of 3.5 years (maximum, 4.5 years; total exposure, 1201 patient-years). On-treatment AEs were reported in 94% of patients (exposure-adjusted rate, 3688 events/1000 patient-years). The most frequently reported on-treatment AEs were respiratory tract infection, headache, bronchitis, and asthma worsening. Seventy-nine (23%) patients experienced 1 or more on-treatment serious AEs; there were 6 deaths, none of which were assessed as related to mepolizumab. For patients with 156 weeks or greater enrollment, the exacerbation rate was 0.74 events/y (weeks 0¿156), a 56% reduction from the off-treatment period between DREAM and COLUMBA. For all patients, at the first postbaseline assessment, the mean Asthma Control Questionnaire 5 score was reduced by 0.47 points, and blood eosinophil counts were reduced by 78%, with similar improvements maintained throughout the study. The immunogenicity profile (8% anti-drug antibodies) was consistent with previous studies. Conclusion: These data support the long-term safety and efficacy of mepolizumab in patients with SEA.